Anaerobic bacterium as a drug for cancer gene therapy
AssigneeAnaeropharma Science, Inc.
InventorsMinoru Fujimori, Shun'ichiro Taniguchi, Jun Amano, Kazuyuki Yazawa, Yasunobu Kano, Toshiyuki Nakamura, Takayuki Sasaki
Life of this patent
Estimating the term…
Abstract
The present invention provides a bacterium belonging to the genus Bifidobacterium, by which DNA coding for a protein having an antitumor activity or DNA coding for a protein having the activity of converting a precursor of an antitumor substance into the antitumor substance is delivered to tumor tissues specifically under anaerobic conditions thereby expressing the protein encoded by the DNA, as well as a pharmaceutical composition comprising said anaerobic bacterium.
Claims24
A nonpathogenic bacterium of the genus Bifidobacterium, comprising a vector that comprises:
- a) a Bifidobacterium histone-like DNA binding protein (HU protein) promoter, a DNA sequence downstream of the promoter that encodes i) a protein with anti-tumor activity or ii) a protein that converts a precursor of an antitumor substance into an antitumor substance, and a HU protein terminator downstream of the DNA sequence;
- and
- b) a selective marker selected from the group consisting of antibiotic resistance markers, nutritional requirement markers, and medium selection markers.
Dependencies are inferred from the claim text.